FDA questions Amgen drug for prostate cancer - USA TODAY

USA TODAY

FDA questions Amgen drug for prostate cancer USA TODAY WASHINGTON – Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects. Benefit of Bone Drug in Prostate Cancer in DoubtMedPage Today FDA doubts benefits of Amgen drug for prostate cancerGlobalPost all 222 news articles »

Experimental Drug Shows Promising Results For Men With Prostate Cancer - NY1

International Business Times

Experimental Drug Shows Promising Results For Men With Prostate Cancer NY1 An experimental drug seems to be improving outcomes in men with extremely advanced prostate cancer, and one of the city's top cancer centers is playing a key role in the research. NY1's Kafi Drexel filed the following report. Prostate Cancer Drug: How to Find Clinical Trials of Promising MedInternational Business Times all 15 news articles »